vs
拜玛林制药（BMRN）与Reddit, Inc.（RDDT）财务数据对比。点击上方公司名可切换其他公司
拜玛林制药的季度营收约是Reddit, Inc.的1.2倍（$874.6M vs $725.6M），Reddit, Inc.净利率更高（34.7% vs -5.3%，领先40.0%），Reddit, Inc.同比增速更快（69.7% vs 17.0%），Reddit, Inc.自由现金流更多（$263.6M vs $58.9M），过去两年Reddit, Inc.的营收复合增速更高（72.8% vs 16.1%）
拜玛林制药是总部位于美国加利福尼亚州圣拉斐尔的生物技术企业，在美洲、亚洲、欧洲多地设有办事机构及生产设施，核心业务聚焦酶替代疗法研发，是全球首个推出Ⅰ型粘多糖贮积症治疗药物拉罗尼酶及苯丙酮尿症治疗药物的企业。
Reddit是美国知名的社交新闻聚合与论坛类社交媒体平台，注册用户可发布链接、文字帖、图片、视频等各类内容，其他用户可对内容进行点赞或点踩，内容按主题归类到用户创建的子板块中，获赞更高的内容会排在板块前列，热度足够的内容还将展示在全站首页。
BMRN vs RDDT — 直观对比
营收规模更大
BMRN
是对方的1.2倍
$725.6M
营收增速更快
RDDT
高出52.6%
17.0%
净利率更高
RDDT
高出40.0%
-5.3%
自由现金流更多
RDDT
多$204.7M
$58.9M
两年增速更快
RDDT
近两年复合增速
16.1%
损益表 — Q4 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $874.6M | $725.6M |
| 净利润 | $-46.6M | $251.6M |
| 毛利率 | 68.5% | 91.9% |
| 营业利润率 | -5.1% | 31.9% |
| 净利率 | -5.3% | 34.7% |
| 营收同比 | 17.0% | 69.7% |
| 净利润同比 | -137.3% | 254.2% |
| 每股收益（稀释后） | $-0.22 | $1.24 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收BMRNRDDT
| Q4 25 | $874.6M | $725.6M | ||
| Q3 25 | $776.1M | $584.9M | ||
| Q2 25 | $825.4M | $499.6M | ||
| Q1 25 | $745.1M | $392.4M | ||
| Q4 24 | $747.3M | $427.7M | ||
| Q3 24 | $745.7M | $348.4M | ||
| Q2 24 | $712.0M | $281.2M | ||
| Q1 24 | $648.8M | $243.0M |
净利润BMRNRDDT
| Q4 25 | $-46.6M | $251.6M | ||
| Q3 25 | $-30.7M | $162.7M | ||
| Q2 25 | $240.5M | $89.3M | ||
| Q1 25 | $185.7M | $26.2M | ||
| Q4 24 | $124.9M | $71.0M | ||
| Q3 24 | $106.1M | $29.9M | ||
| Q2 24 | $107.2M | $-10.1M | ||
| Q1 24 | $88.7M | $-575.1M |
毛利率BMRNRDDT
| Q4 25 | 68.5% | 91.9% | ||
| Q3 25 | 82.0% | 91.0% | ||
| Q2 25 | 81.8% | 90.8% | ||
| Q1 25 | 79.7% | 90.5% | ||
| Q4 24 | 81.8% | 92.6% | ||
| Q3 24 | 74.7% | 90.1% | ||
| Q2 24 | 81.7% | 89.5% | ||
| Q1 24 | 80.7% | 88.6% |
营业利润率BMRNRDDT
| Q4 25 | -5.1% | 31.9% | ||
| Q3 25 | -6.0% | 23.7% | ||
| Q2 25 | 33.5% | 13.6% | ||
| Q1 25 | 30.0% | 1.0% | ||
| Q4 24 | 21.6% | 12.4% | ||
| Q3 24 | 15.3% | 2.0% | ||
| Q2 24 | 16.9% | -11.0% | ||
| Q1 24 | 13.6% | -242.5% |
净利率BMRNRDDT
| Q4 25 | -5.3% | 34.7% | ||
| Q3 25 | -4.0% | 27.8% | ||
| Q2 25 | 29.1% | 17.9% | ||
| Q1 25 | 24.9% | 6.7% | ||
| Q4 24 | 16.7% | 16.6% | ||
| Q3 24 | 14.2% | 8.6% | ||
| Q2 24 | 15.1% | -3.6% | ||
| Q1 24 | 13.7% | -236.7% |
每股收益（稀释后）BMRNRDDT
| Q4 25 | $-0.22 | $1.24 | ||
| Q3 25 | $-0.16 | $0.80 | ||
| Q2 25 | $1.23 | $0.45 | ||
| Q1 25 | $0.95 | $0.13 | ||
| Q4 24 | $0.65 | $4.76 | ||
| Q3 24 | $0.55 | $0.16 | ||
| Q2 24 | $0.55 | $-0.06 | ||
| Q1 24 | $0.46 | $-8.19 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $1.3B | $953.6M |
| 总债务越低越好 | — | — |
| 股东权益账面价值 | $6.1B | $2.9B |
| 总资产 | $7.6B | $3.2B |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
现金及短期投资BMRNRDDT
| Q4 25 | $1.3B | $953.6M | ||
| Q3 25 | $1.3B | $911.7M | ||
| Q2 25 | $1.2B | $734.1M | ||
| Q1 25 | $1.0B | $635.7M | ||
| Q4 24 | $942.8M | $562.1M | ||
| Q3 24 | $675.4M | $515.9M | ||
| Q2 24 | $972.1M | $468.0M | ||
| Q1 24 | $747.0M | $968.5M |
股东权益BMRNRDDT
| Q4 25 | $6.1B | $2.9B | ||
| Q3 25 | $6.1B | $2.6B | ||
| Q2 25 | $6.0B | $2.4B | ||
| Q1 25 | $5.8B | $2.2B | ||
| Q4 24 | $5.7B | $2.1B | ||
| Q3 24 | $5.4B | $2.0B | ||
| Q2 24 | $5.3B | $1.9B | ||
| Q1 24 | $5.1B | $1.8B |
总资产BMRNRDDT
| Q4 25 | $7.6B | $3.2B | ||
| Q3 25 | $7.6B | $2.9B | ||
| Q2 25 | $7.5B | $2.6B | ||
| Q1 25 | $7.1B | $2.4B | ||
| Q4 24 | $7.0B | $2.3B | ||
| Q3 24 | $6.9B | $2.2B | ||
| Q2 24 | $7.1B | $2.1B | ||
| Q1 24 | $6.9B | $2.0B |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $99.6M | $266.8M |
| 自由现金流经营现金流 - 资本支出 | $58.9M | $263.6M |
| 自由现金流率自由现金流/营收 | 6.7% | 36.3% |
| 资本支出强度资本支出/营收 | 4.7% | 0.4% |
| 现金转化率经营现金流/净利润 | — | 1.06× |
| 过去12个月自由现金流最近4个季度 | $725.0M | $684.2M |
8季度趋势，按日历期对齐
经营现金流BMRNRDDT
| Q4 25 | $99.6M | $266.8M | ||
| Q3 25 | $368.7M | $185.2M | ||
| Q2 25 | $185.3M | $111.3M | ||
| Q1 25 | $174.4M | $127.6M | ||
| Q4 24 | $185.6M | $90.0M | ||
| Q3 24 | $221.5M | $71.6M | ||
| Q2 24 | $118.8M | $28.4M | ||
| Q1 24 | $47.0M | $32.1M |
自由现金流BMRNRDDT
| Q4 25 | $58.9M | $263.6M | ||
| Q3 25 | $340.2M | $183.1M | ||
| Q2 25 | $168.2M | $110.8M | ||
| Q1 25 | $157.6M | $126.6M | ||
| Q4 24 | $166.1M | $89.2M | ||
| Q3 24 | $203.0M | $70.3M | ||
| Q2 24 | $97.4M | $27.2M | ||
| Q1 24 | $20.9M | $29.2M |
自由现金流率BMRNRDDT
| Q4 25 | 6.7% | 36.3% | ||
| Q3 25 | 43.8% | 31.3% | ||
| Q2 25 | 20.4% | 22.2% | ||
| Q1 25 | 21.2% | 32.3% | ||
| Q4 24 | 22.2% | 20.8% | ||
| Q3 24 | 27.2% | 20.2% | ||
| Q2 24 | 13.7% | 9.7% | ||
| Q1 24 | 3.2% | 12.0% |
资本支出强度BMRNRDDT
| Q4 25 | 4.7% | 0.4% | ||
| Q3 25 | 3.7% | 0.4% | ||
| Q2 25 | 2.1% | 0.1% | ||
| Q1 25 | 2.3% | 0.2% | ||
| Q4 24 | 2.6% | 0.2% | ||
| Q3 24 | 2.5% | 0.4% | ||
| Q2 24 | 3.0% | 0.4% | ||
| Q1 24 | 4.0% | 1.2% |
现金转化率BMRNRDDT
| Q4 25 | — | 1.06× | ||
| Q3 25 | — | 1.14× | ||
| Q2 25 | 0.77× | 1.25× | ||
| Q1 25 | 0.94× | 4.88× | ||
| Q4 24 | 1.49× | 1.27× | ||
| Q3 24 | 2.09× | 2.40× | ||
| Q2 24 | 1.11× | — | ||
| Q1 24 | 0.53× | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
BMRN
| VOXZOGO | $273.4M | 31% |
| VIMIZIM | $205.5M | 24% |
| PALYNZIQ | $125.3M | 14% |
| NAGLAZYME | $120.2M | 14% |
| Other | $49.4M | 6% |
| ALDURAZYME | $49.4M | 6% |
| KUVAN | $23.3M | 3% |
| Royalty And Other | $15.2M | 2% |
| ROCTAVIAN | $12.8M | 1% |
RDDT
| Advertising | $689.7M | 95% |
| Other Revenue | $35.9M | 5% |
